- Home
- AEI vs MYNZ Comparison
AEI vs MYNZ Comparison
Compare AEI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEI
- MYNZ
- Stock Information
- Founded
- AEI 2014
- MYNZ 2021
- Country
- AEI United States
- MYNZ Germany
- Employees
- AEI N/A
- MYNZ N/A
- Industry
- AEI Building operators
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- AEI Real Estate
- MYNZ Health Care
- Exchange
- AEI Nasdaq
- MYNZ Nasdaq
- Market Cap
- AEI 8.8M
- MYNZ 7.2M
- IPO Year
- AEI N/A
- MYNZ 2021
- Fundamental
- Price
- AEI $0.93
- MYNZ $3.12
- Analyst Decision
- AEI
- MYNZ Buy
- Analyst Count
- AEI 0
- MYNZ 2
- Target Price
- AEI N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- AEI 46.3K
- MYNZ 119.2K
- Earning Date
- AEI 05-14-2025
- MYNZ 05-06-2025
- Dividend Yield
- AEI N/A
- MYNZ N/A
- EPS Growth
- AEI N/A
- MYNZ N/A
- EPS
- AEI N/A
- MYNZ N/A
- Revenue
- AEI $21,115,899.00
- MYNZ $893,991.00
- Revenue This Year
- AEI N/A
- MYNZ $42.95
- Revenue Next Year
- AEI N/A
- MYNZ N/A
- P/E Ratio
- AEI N/A
- MYNZ N/A
- Revenue Growth
- AEI N/A
- MYNZ N/A
- 52 Week Low
- AEI $0.46
- MYNZ $0.18
- 52 Week High
- AEI $2.61
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- AEI 52.82
- MYNZ 39.55
- Support Level
- AEI $0.90
- MYNZ $3.03
- Resistance Level
- AEI $1.00
- MYNZ $3.31
- Average True Range (ATR)
- AEI 0.10
- MYNZ 0.34
- MACD
- AEI 0.01
- MYNZ 0.06
- Stochastic Oscillator
- AEI 69.60
- MYNZ 55.24
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.